Donald Davis (D-NC)

Old Drugs, New Cures Act

H.R. 2542 · House bill Health

A Democratic bill with 1 Republican cosponsor · See the cosponsor

Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

The "Old Drugs, New Cures Act" aims to amend the Social Security Act regarding how drugs are treated under Medicare and Medicaid. It introduces a new designation called a "priority research drug" for certain covered outpatient drugs. To qualify, a drug must have been approved for at least 10 years and the manufacturer must be investigating it for a new indication that addresses a significant unmet medical need. This new indication must also be for a disease or condition with high prevalence among beneficiaries of Federal health care programs. The bill ensures these priority research drugs are not treated as line extensions of existing drugs when calculating manufacturer rebates.

Yes· 3 of 9

  • Scored +2

    Would business owners be better off under this?

    The bill benefits pharmaceutical manufacturers by exempting certain priority research drugs from line extension rebate requirements.

  • Scored +2

    Does this put more money into scientific research?

    The bill creates a pathway to incentivize pharmaceutical companies to invest in research for new indications.

  • Scored +2

    Does this make health care easier to get in general?

    The bill aims to stimulate research into new treatments for significant unmet medical needs.

The opposite

  • Scored -3

    Does this lower the price of prescription medicines?

    The bill exempts specific new indications from rebate calculations, which could potentially reduce the downward pressure on drug prices.

  • Scored -2

    Does this reduce what the federal government spends?

    By exempting priority research drugs from certain rebate rules, the bill may reduce the total rebate revenue returned to the government.